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The paradigm of ribosome usage in protein translation has shifted from a stance 
proposed as scientists began to unpick the genetic code that each mRNA was 
partnered by its own, unique ribosome to a rapid reversal of this view that ribosomes 
are completely interchangeable and simply recruited to mRNAs from a completely 
homogenous cellular pool.  Evidence that the ribosomal proteome, ribosomal gene 
transcriptome and ribosome protein and RNA modifications differ between cells and 
tissues points to the fact that ribosomes are heterogeneous in their composition and 
have a degree of specialisation in their function.  It has also been posited that the 
tissue-specificity of ribosome diseases provides an indication of functional ribosome 
heterogeneity, but there are substantial caveats to this interpretation.  Only now have 
proteomic technologies developed to a level enabling accurate stoichiometric 
comparison of the abundance of specific ribosomal proteins in actively translating 
ribosomes and to measure protein in non-denatured ribosomes.  This poises the field 
for the provocation that ribosome heterogeneity offers a novel and powerful inroad 
for the pharmacological targeting of disease.  Such ribosome-targeted treatments 
may extend beyond specific ribosomopathies through strategies such as targeting 
features of ribosomes that are unique to diseased cells, particularly cancer cells, or 
to activated immune cells, as well as augmenting the action of other drugs through 
weakening the production of new proteins in target tissues.  We may also be able to 
 2 
harness the potential power in ribosome diversity and specialism to better tune 
synthetic biology for the production of pharmaceutical proteins. 
 





1. Discovery of the ribosome 
 
The ribosome was first described by George Palade in the 1950s, who observed 
dense intracellular particles using electron microscopy (EM) [1].  Palade’s initial 
terminology ‘microsome’ caused confusion among biologists because the microsome 
fraction of the cell separated physically includes protein and lipid.  The protein and 
lipid component was viewed as contaminant of the particulate matter considered to 
be the microsome fraction by some biologists, whereas others considered the protein 
and lipid to be the microsomal fraction and the particulate matter the contaminant.  
The suggested term ‘ribonucleoprotein particles of the microsome fraction’ was, 
rightly, considered cumbersome, hence adoption of the term ribosome.  Palade, 
along with Albert Claude and Christian de Duve, was awarded the Nobel Prize in 
1974 for discovery of the ribosome. 
 
2. Structure of the ribosome 
 
At the simplest level of description, the ribosome is a complex of RNA and protein - a 
ribonucleoprotein.  The size of the ribosome components is measured in Svedberg 
units (S), a measure of the rate of sedimentation during centrifugation.  In both 
bacterial and eukaryotic cells, the ribosome (total 60S in bacteria and 80S in 
eukaryotes) has a smaller and larger subunit.  The smaller subunit (30S in bacteria, 
40S in eukaryotes) contains single ribosomal RNA (rRNA) chain (16S and 18S in 
bacterial and eukaryotes, respectively).  There are two RNA chains in the 50S 
bacterial large subunit (23S and 5S) and three in the 60S eukaryotic large subunit 
(28S, 5.8S and 5S).  Ribosomal RNA is transcribed by RNA polymerase I. The 
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bacterial small subunit typically contains ~22 proteins and the eukaryotic small 
subunit ~32 proteins; 15 of these are common to both.   The bacterial large subunit 
typically contains ~32 proteins and the eukaryotic large subunit contains ~45 
proteins, of which 18 are common to both.  The ribosomal protein nomenclature 
system initially evolved organically, leading to some complexity and potential 
confusion.  Most proteins are numbered sequentially for each of the small and large 
subunit with a prefix of S denoting a protein of the small ribosomal subunit and L a 
protein of the large subunit.   A recommended system for universal nomenclature is 
to also use the prefix b (e.g. bS1; bL9), e (e.g. eS1; eL6) or u (e.g. uS2; uL1) to 
denote proteins that are exclusively bacterial, exclusively eukaryotic or universal, 
respectively [2].  This system is used throughout this article. The protein and rRNA 
makeup of the bacterial and eukaryotic ribosome is summarised in Figure 1.  Since 
the turn of the millennium, X-ray crystallography has revealed the atomic structure of 
the ribosome at increasing resolution. Published structures include some with the 
ribosome in complex with the mRNA being translated and with the tRNAs 
responsible for assembly of their amino acid cargoes (reviewed in [3]). 
 
3. Early history of the concept of ribosome heterogeneity  
 
Palade suggested the ribosome could be a heterogeneous particle based on his 
early observation of apparent size and shape difference between the dense 
particulate matter he observed by EM.  Francis Crick was an enthusiastic proponent 
of a ‘one gene-one ribosome-one protein hypothesis’, which encompassed the 
concept of there being a bespoke ribosome for each protein – ribosome 
heterogeneity at its most extreme [4].  However, in 1963, only three years after Crick 
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proposed this model, the field underwent a complete volte-face.  Landmark 
experiments by Brenner and co-workers demonstrated that E. coli cells used 
ribosomes already present in the cell before phage infection to translate the phage 
proteins [5], leading to the view that ribosomes are completed non-specialised and 
simply synthesise the protein determined by the message present.   The view that 
the ribosome is a largely passive element of the cellular gene-decoding machinery 
that simply responds non-discriminately to translate whichever mRNAs are 
transcribed prevailed over the several decades that followed and indeed is still the 
way ribosomes and their function are preened in most modern textbooks. 
 
4. A re-evaluation of the position on ribosome heterogeneity 
 
4.1. Tissue-specific presence of ribosomal elements 
 
Throughout the 1980s and 1990s reports of differential expression of specific 
ribosomal proteins or in the rRNA content under different conditions or in different 
cell types in a variety of model organisms began to emerge.  For example, a GUS ( 
β-glucuronidase) reporter sequence fused to the promoter sequence of each of 2 
paralogues of the uL16 ribosomal protein in Arabidopsis revealed differential 
expression in proliferating versus non-proliferating tissue [6] and changes in the 
expression and modification of specific ribosomal proteins were observed the slime 
mould Dictyostelium discoideum during the transition from unicellular growth to the 
multicellular fruiting body [7]. 
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A substantial body of experimental observations now points indirectly to the 
likelihood that the cell alters ribosome synthesis, and the specific ratios of the 
ribosomal components, under a variety of conditions.  A bioinformatic analysis of the 
burgeoning body of RNAseq data focused on ribosomal protein genes found that 
transcripts for 80%–90% of ribosomal protein genes were present in a stoichiometry 
that spanned a range of less than threefold and with little tissue specificity [8]. 
Nonetheless, this reveals either that not all ribosomes contain all protein components 
in equimolar amounts or that there is regulated translation and/or differential turnover 
of ribosomal proteins.  Moreover, the analysis revealed that several of seven 
annotated ribosomal protein subsidiary genes appeared to be transcribed in a tissue-
specific manner, including RPL10L in testis and RPL3L in muscle.  Also, work from 
this author’s laboratory probing the role of a zinc-sensitive transcription factor 
ZNF658 through determining the response of the transcriptome to its knockdown 
revealed that of 77 genes up-regulated 29 were ribosomal proteins or annotated as 
ribosomal protein pseudogenes [9].  It is possible that these are, in fact, functional 
genes repressed by ZNF658 when the zinc supply is adequate and expressed to 
alter ribosome composition and thus mRNA preference adaptively to conditions of 
zinc restriction.   
 
Other evidence demonstrates more-directly that the ribosomal population of the cell 
differs in its makeup in a way that is both dynamic and cell-specific and that the cell 
invokes ribosomal protein paralogs as an element of likely functional variability.   A 
body of work reveals that different cell and tissue types have characteristic ribosomal 
protein transcript profiles.  For example, analysis of the heterogeneity of expression 
of 90 ribosomal protein genes, including 19 paralogs, in a panel of human tissues, 
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primary cells, and tumours revealed that approximately one quarter of human 
ribosomal proteins are expressed in a tissue-specific manner [10]. Ribosomal protein 
genes in yeast cells (Saccharomyces cerevisiae) exist in pairs created by gene 
duplication; it was shown recently that one member is most active  under normal 
growth conditions and the other under conditions of stress, leading to modification of 
ribosome composition in response to changes in growth conditions  [11].  Other work 
presenting evidence of differential use of the ribosomal protein paralogs for likely 
(though still unproven) functional consequence includes studies on the switching 
from use in skeletal muscle of predominantly RPuL3 to RPuL3L in response to an 
anabolic stimulus [12] .  Mechanisms underlying the switching between use of 
ribosomal protein paralogs are potentially diverse; currently we have knowledge of 
only isolated specific examples such as for the switch between RPeL22L1 and 
RPeL22, which is via RPeL22 destabilising the mRNA for RPeL22L1 through a direct 
binding interaction [13].  
 
Speculatively, detailed work in polarised cells, such the intestinal epithelial cell 
(enterocyte) and neurone, may reveal variation in ribosome composition at the 
subcellular level.  Polarised distribution of mRNA, presumably to achieve translation 
into the corresponding proteins at their sites of function, is observed in polarised 
cells, as well-established for the enterocyte [14, 15].  Localised mRNA translation to 
protein would be further honed by a corresponding polarised distribution of variant 
ribosomes matched to translation of the polarised mRNAs.    
 
4.2. Variation in ribosome interacting proteins 
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The contribution of differences in protein content to variations in ribosomal structure 
extend beyond differences in ribosomal protein content to differences in composition 
with respect to other interacting proteins, of which a recent study revealed several 
hundred [16].  Significantly, this work uncovered the fact that the enzyme pyruvate 
kinase, in a non-canonical role, was associated preferentially with the ribosomes of 
the ER compared with cytosolic ribosomes in mouse embryonic stem cells.  This 
highlights again the likelihood that ribosomal heterogeneity at the sub-cellular level 
may be important functionally.  It also points to the ribosome interacting proteins as 
are a potential site to target pharmacologically to achieve a desired specific 
functional intervention. 
 
4.3. Variation in ribosome protein post-translational modification 
 
Protein posttranslational modification comprises a further level of potential variation 
between ribosomes in their protein composition that contributes to heterogeneity and 
has potential effects on function.  As a principle, it has been known for many years 
that the core ribosomal proteins undergo posttranslational modification. 
Phosphorylation and ubiquitination have been studied most extensively (reviewed in 
[17].   Indeed, phosphorylation of RPeS6 is so well-established as a downstream 
effect of activation of the mTORC pathways and also of physiological or 
pharmacological neurone activation in mice that it is used experimentally as robust 
marker of both processes [18, 19].  Nonetheless, the functional effects of this 
reproducible response are less evident.  The phenotype of RPeS6 phosphorylation-
deficient mice is subtle and tissue-specific, including smaller pancreatic beta cells 
and impaired glucose homeostasis [20, 21]. 
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The finding that the ribosomal protein RPL26 is the major target for the protein 
modification UFMylation provides compelling evidence for a posttranslational 
modification of a ribosomal protein that has functional effects.  UFMylation comprises 
addition of an 85-amino acid modifier, ubiquitin fold modifier 1 (UFM1), to lysine 
residues on target proteins, similar to ubiquitination.  Until recently, although known 
to be essential for brain and hematopoietic development [22, 23] the biological 
function and protein targets of this modification were unknown.  UFMylome analysis 
in human (K562 erythroleukemia) cells engineered to lack either UFMylation or de-
UFMylation revealed RPL26 as the principal target of this modification.  The work 
uncovered a dynamic cycle of UFMylation and de-UFMylation of RPL26 by enzymes 
at the cytoplasmic surface of the endoplasmic reticulum in close proximity to the 
SEC61 translocon, indicating that RPL26 UFMylation is a specific functional 
ribosomal modification that plays a role in protein biogenesis in the early secretory 
pathway [24].  
 
Abnormality in ribosomal protein post-translational modification has been uncovered 
as the basis for some human diseases.  A striking example is the intimate 
relationship between phosphorylation of RPuS19 and Parkinson’s disease [25].   The 
kinase LRRK2, which phosphorylates RPuS17, RPuS19, and RPeS27, is mutated in 
familial and sporadic forms of the disease.  In Drosophila, mutation of the substrate 
site on RPuS19 rescues the toxicity of mutant LRRK2 whereas incorporation of the 
phosphomimetic form of RPuS19 causes neurotoxicity, providing evidence for a 
causal relationship.  Also, human post-mortem brain samples from Parkinson’s 
disease patients with the LRRK2 mutation revealed hyperphosphorylation of 
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RPuS19.  Together, this body of evidence supports strongly the premise that 
RPuS19 phosphorylation has substantial functional effects.             
 
Although there are myriad unequivocal strands of evidence that ribosomal protein 
posttranslational modification is observed and that it at least can be functional in 
some instances, there remains a question concerning whether or not these 
modifications can be bespoke to specific, individual ribosomes to bestow 
heterogeneity and functional diversity either within or between cells.   
 
4.4. Variation in ribosomal RNA sequence and post-transcriptional 
modification 
 
We should also explore the potential for ribosomes to be divergent at the level of the 
rRNA, as well as in terms of ribosomal protein composition.  Should this emerge as a 
level of variance with impactful functional relevance then gene-therapy approaches 
that target ribosomal RNA diversity may be another avenue of therapeutic 
intervention through exploiting ribosome heterogeneity to develop.   
 
The four eukaryotic rRNAs are encoded by multiple copies of ribosomal DNA (rDNA) 
on different chromosomes [26-28].  The 18 and 5.8 and 28S rRNAs are transcribed 
as a 45S rRNA precursor that undergoes post-transcriptional processing to yield the 
mature rRNAs.  Mapping of rRNA sequence data to these different rDNAs indicates 
that many rRNA alleles are expressed in a tissue-specific manner [29-31].  
Intriguingly, the binding sequence for the zinc-regulated transcription factor ZNF658, 
which, as mentioned above, may have a role in the transcription of specific ribosomal 
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protein variants, occurs in multiple copies in the 45S rRNA precursor 5’ to the start of 
the mature 18S rRNA and is also present 5’ to each of the mature 5.8 and 28S  
rRNA sequences [9].  Though unproven, it is possible that these ZTREs provide sites 
through which the cell modifies 45S rRNA processing in response to zinc availability.  
Variation in these ZNF658 biding sequences (ZTREs) between the multiple rDNAs 
may, speculatively, play a role alongside refinement of the ribosomal protein 
complement produced in adapting the cellular ribosome makeup to respond to 
changes in the zinc supply, which requires a tightly regulated homeostatic response 
across the phyla [32].   An understanding of switching between rRNA genes and of 
its likely functional importance is particularly well advanced with regard to zebrafish 
development.  Sequencing the ribosomal transcriptome from eggs, embryos and 
adult tissue has revealed that for the 5S rRNA [33]  then the 18, 5.8 and 28S 
products of the common 45S precursor [34] a switch from maternal sequences to 
somatic sequences, mapping to different rRNA genes. Although demonstration of 
functional importance is still rudimentary, in silico work suggests that expansion 
segments in 18S rRNA that appear to be involved directly in ribosome–mRNA 
interactions may preferentially interact with specific mRNA genes. 
      
In addition to selective rDNA transcription in specific tissues, and potentially under 
other different conditions, variation at the level of rRNA occurs also through post-
transcriptional modification.  Approximately 2% (over 200 sites in humans) of rRNA 
nucleotides are modified.  The most common modification is 2’-O-methyation of the 
sugar (reviewed in [35]) but pseudouridylation, ribosylation, base methylation and 
acetylation is also observed [17].  The view generally held is that rRNA chemical 
modifications stabilise secondary and tertiary structures, which is a plausible 
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mechanism through which functional effect may be achieved. Modifications at some 
sites are sub-stoichiometric, commensurate with, though not sufficient for, them 
being a layer of functional ribosomal specialisation (reviewed in [36]).  For example, 
of 112 sites modified by pseudouridylation in yeast, 18 were modified on fewer than 
85% of ribosomes [37]. In human HeLa and HCT116 cells, approximately one- third 
of 2’-O-methylation sites were fractionally, rather than fully, modified. Importantly, 
there were distinct differences between the two cell lines at some sites, adding to the 
evidence for ribosome specialisation specifically at the level of rRNA post-
translational modification [38].  
 
4.5. Do observed differences in ribosome structure have functional effects? 
 
The most obvious manner in which ribosome specialisation is likely to play out 
functionally is through it being a mechanism to target ribosomes specifically to the 
translation of specific mRNAs or affect the efficiency with which specific mRNAs are 
translated. However, there are important caveats to observations that are 
commensurate with the view that ribosomes are heterogeneous in a manner that 
targets ribosomes of specific composition to the translation of specific transcripts. 
For example, while variation in ribosome composition may be observed 
unequivocally, specificity of interaction between ribosomes of specific composition 
and particular mRNAs has not been demonstrated directly.  A recent analysis that 
raises pertinent questions about functional relevance highlights this current 
challenge to the field [39].  For example, could variation in the composition of 
microsomes be merely reflective of a level of tolerance in the process of ribosome 
quality control?  Some studies report very similar effects on mRNA translation after 
 13 
knockdown of diverse ribosomal proteins, which the authors proffer may simply be a 
manifestation of a general defect in ribosome function as may be the result of overall 
reduced ribosome numbers, which, in turn, could affect differentially subclasses of 
mRNAs.  The authors recommend controls to validate functional diversity, including 
gain-of-function assays and showing that selective effects on translation of specific 
mRNAs can be induced under physiological conditions.  
 
4.6. New inroads through technological advances 
 
Despite longstanding challenges, however, the field now stands poised for rigorous 
evaluation of the penetration of functional ribosome heterogeneity because 
proteomic technologies have now developed to a level enabling accurate 
stoichiometric comparison of the abundance of specific ribosomal proteins in in 
actively translating ribosomes.  Such an analysis was achieved for 15 ribosomal 
proteins in mouse embryonic stem cells using the technique of selected reaction 
monitoring (SRM) mass spectrometry [40].  The technique determines absolute 
abundance of a specific protein by comparison of the signal strength for known 
peptides with the signal strength for a spiked heavy isotope standard of the same 
peptides.  Nine of the 15 ribosomal proteins (five of the large subunit and four of the 
small subunit) were present in quantities that did not vary significantly, interpreted to 
reveal ribosomal components that were core to translating all mRNAs in this cell 
type.  Two proteins (of the large subunit) were present at levels only slightly lower 
than these but four of the ribosomal proteins measured (two in each of the large and 
small ribosome subunits) were present at only 60%–70% of this level, indicating their 
incorporation in only a subset of ribosomes of likely selective function.   Two of these 
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non-stoichiometric ribosomal proteins (one on each subunit; RPSeS25 and RPuL1) 
were selected for analysis of the mRNA populations to which ribosomes 
incorporating them bind on the basis that they occupy a position in the ribosome that 
flanks the mRNA exit tunnel. This analysis, comprising mRNA footprinting and 
RNAseq before and after CRISPR/Cas-mediated knockdown and affinity purification 
of mRNAs bound to FLAG-tagged immunoprecipitates, revealed that they are 
incorporated in ribosomes that bind selectively to subsets of mRNAs that differ for 
each of the two individual ribosomal proteins.  Some RNA footprints were enriched 
and others depleted after knockdown, revealing both preferential and disfavoured 
binding interactions. Interestingly, there was also a tendency for opposite enrichment 
or depletion of sub-pools of mRNAs related by opposite function. For example, 
footprints for ribosomes containing RPuL1 were enriched in genes promoting growth 
or implicated in cancer metastasis but depleted in transcripts functioning in the stress 
response and cell death.  Arguably, this work provides compelling direct evidence 
that ribosomes differencing in composition with respect to their protein content are 
responsible for the translation of a subset of transcripts with specific cellular 
functions.  A finding of particular potential significance to potentially exploiting 
ribosome heterogeneity as a therapeutic target was that RPeS25-containing 
ribosomes were significantly over-represented among the transcripts of all 
components of the vitamin B12 pathway (transport, cellular uptake and utilisation). 
This finding hints at the possibility that ribosome heterogeneity may operate on the 
components of entire metabolic pathways, akin to operons in bacterial cells, and thus 
be a particularly powerful lever through which to intervene in a given pathway.   
A further unanswered question concerning ribosome heterogeneity is to what extent 
the potential enormous level of diversity that arises from the known number of 
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ribosomal protein variants, possible differences in ribosome protein stoichiometry, 
rDNA variants and rRNA and ribosomal protein modification all in combination is 
actually exploited by the cell.  Although the body of data on all of these features 
demonstrates that ribosomes in different cells in the same organism can differ per 
se, it is not sufficiently granular to reveal what extent of the capacity for individual 
ribosomes to differ from each other is actually used.  We can address this question 
only by observing ribosomes on an individual basis.  One approach that offers 
promise and has been used to observe the assembly and stoichiometry of individual 
ribosomal proteins in ribosomal particles of bacterial, plant and human origin is 
native mass spectrometry.  Testing the capacity of this technique to reveal details of 
the human 40S subunit resolved a minor population of particles lacking either the 
S25 or S10 protein and also allowed detection of bound viral RNA fragments [41].  
Cryo-electron microscopy also offers promise to observe the composition of 
individual ribosomes.  The technique has been used to visualise the structure of the 
human and Drosophila ribosome [42] but, until a very recent report (made available 
in pre-print form, pending validation by peer-review, in January 2020 [43]) had not 
been applied to observing ribosome heterogeneity.  A challenge to overcome was to 
achieve adequate resolution of individual structural differences using a technique 
that averages data from many complexes into an individual structure.  In this recent 
study, the level of purification achieved by sucrose-gradient centrifugation was 
adequate to generate a dataset with average resolution of 3.5 Å from Drosophila 
testis and 3.0 Å from ovary, which allowed the generation of atomic models for 80S 
ribosomal complexes from both tissues.  Analysis of the same ribosomal 
preparations by quantitative mass spectrometry revealed that ribosomal protein 
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paralog switching made the biggest contribution to ribosome heterogeneity, and 
mapping the switching paralogs onto the ribosome structures revealed locations at 
the surface, suggesting that switching could alter the ribosome surface and hence 
enable different proteins to regulate translation.  A further level of purification of 
ribosomal sub-populations, for example by affinity purification based on use of 
antibodies specific to particular ribosomal protein variants, may also prove effective 
in yielding samples suitable for visualisation of differences at high resolution.  
 
5. Ribosomopathies and associated indications of ribosome heterogeneity 
 
Towards the end of the millennium came a discovery that supports directly the 
provocation that ribosomes may be a feature we can target for therapeutic benefit 
and that revealed ribosomal disorders can have effects that are tissue specific.  The 
underlying cause of the disease Diamond-Blackfan Anaemia, a deficiency in the 
production of erythroid precursors in the bone marrow, was found to be abnormality 
in the gene encoding ribosomal protein eS19 [44].  The disease is now linked to 
mutations in over 15 different ribosomal proteins (reviewed in [45]).  Mutations in 
ribosomal protein genes in other diseases, which also have tissue specificity, have 
since been revealed.  These include asplenia in humans associated with loss of 
RPuS2 [46] and a form of hair loss inherited through a mutation of RPeL21 [47].   A 
recent meta-analysis of genome-wide association studies (GWAS) of atrial fibrillation 
that uncovered associations with a missense and a splice donor variant of RPL3L 
[48].  The researchers sourced RNA from the cardiac aorta of 167 people of whom 
two were found to carry the splice donor variant. In both individuals, and in contrast 
to the other 165 people in the sample, an alternative isoform of RPL3L was present.  
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It remains to be established if the variant affects ribosome function and if this has 
any effect on cardiac function.  Other diseases caused by abnormalities in ribosome 
structure that presumably have functional effects include dyskeratosis congenita, in 
which pathogenic mutations result in abnormal patterns of rRNA pseudouridylation 
that promote tumorigenesis through impaired translation of p53 and p27 tumour 
suppressors and of the antiapoptotic factors Bcl-xL and XIAP [49-51].   
 
The number of disorders now shown or identified as likely to have at the root a 
ribosomal dysfunction has expanded as RNAi-based screens have uncovered a 
plethora of ribosome biogenesis factors that encompasses many disease-associated 
proteins and biomarkers (reviewed in [52]).  Table 1 presents a list of diseases in 
which ribosome abnormality has a role and in which tissue-specific symptoms are 
manifest. 
 
These discoveries expand the range of potential therapeutic targets for the treatment 
of not only ribosomopathies but also other diseases in which intervention targeted to 
ribosomal function may be effective.  Thus these discoveries highlight further the 
importance of first developing a robust knowledge base of the extent to which the 
cell exploits the potential capacity for ribosome heterogeneity and of the specific 
relationship between cell types and specific ribosome variants, as well as of 
ribosome variant functionality.   
 
Tissue-specific effects of ribosomal abnormalities are also observed in model 
organisms.  For example, the various different Drosophila minute phenotypes of 
small bristles and delayed development mapped to numerous different ribosomal 
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protein loci have distinctive features, one of which is a specific effect on wing growth 
associated with point mutations in RpL38 and RpL5 [81].  Mice carrying mutations in 
the Rpl38 gene, characterised phenotypically by skeletal patterning defects, showed 
perturbed translation of a subset of homeobox mRNAs identified by polysome 
profiling whilst global protein synthesis and Hox mRNA levels were unchanged. This 
phenotype was specific to the Rpl38 gene and not apparent in mice carrying 
mutations in any of five other ribosomal protein genes, demonstrating selectivity the 
relationship between RPeL38 and the affected mRNAs. Also, expression of RPeL38 
was found to be highly enriched in the embryonic tissues affected by the mutation, 
which is commensurate with there being a tissue-specific function of RPeL38 at 
these sites [82].  Male infertility in RPLP1 mutant mice is a second example of a 
ribosomal protein abnormality in mice that manifests in a tissue-specific manner [83].  
 
It has been posited that the different underlying causes of ribosomopathies and their 
different tissue-specific phenotypes provides evidence that ribosome heterogeneity 
exists and has functional consequence.  However, judicious attention to many 
caveats is required to avoid over-interpretation.  Consider, for example, Diamond 
Blackfan Anaemia. Researchers have argued that the bone-marrow-specific effects 
of the causative ribosomal protein mutations reveals that ribosomes that include 
these proteins have specific roles in haematopoiesis.  This argument can be 
challenged, however, by the proposal that an effect of a mutation on ribosome 
activity and overall rate of translation that is global and non-specific may nonetheless 
be manifest in a cell-specific manner.  Most obviously, a rapid rate of cell division 
may make certain cells, including the haematopoietic cells of the bone marrow, more 
susceptible than others (akin to the manner in which some chemotherapies, though 
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generic in action, target the rapidly dividing cancer cells).  However, some 
observations provide a counter-argument to such a proposal.  For example, not 
every ribosomal protein mutation that decreases the rate of protein synthesis is 
manifest as Diamond Blackfan Anaemia.  Mice lacking RPeL29, for example, exhibit 
lower rates of protein synthesis without the symptoms of Diamond Blackfan 
Anaemia, but are small and have fragile bones [84]. Another way a given ribosomal 
protein mutation could manifest as tissue-specific symptoms that could, incautiously, 
be interpreted as evidence for tissue-specific ribosome complements would be if 
specific ribosomal proteins common to all ribosomes bind only to specific mRNAs.  In 
this instance, manifestation of any symptoms of ribosomal protein mutation or 
deficiency would depend purely on whether or not a specific transcript is expressed 
in the tissue in question.  Another model proposed to account for tissue-specific 
effects of abnormality in the fundamental and ubiquitous process of ribosome 
function or assembly that need not invoke the concept of functional ribosome 
heterogeneity pivots on stabilisation of the tumour suppressor p53 via an extra-
ribosomal function of the 5S RNP.  Non-ribosome-associated 5S RNP, resulting from 
defective ribosome assembly, binds to and inhibits the E3 ubiquitin ligase HDM2, 
which removes p53 through targeting the protein for proteasomal degradation [85].   
As a result, cellular p53 levels rise [86-88].   In this model, tissue specificity is based 
on differences in the level of p53 activation in different cell types [89, 90].  Consistent 
with this model being the explanation for tissue-specific effects at least in some 
instances of ribosomopathy is that many such specific effects appear to be p53 
dependent.  For example, symptoms of Treacher Collins syndrome and 5q syndrome 
can be rescued by inhibiting p53 function [91, 92].   
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6. Ribosome heterogeneity as a potential therapeutic inroad 
 
Current exploitation of the ribosome as a druggable target includes the treatment of 
Duchenne muscular dystrophy with ataluren, which is effective in the by virtue of its 
action to promote read-through by the ribosome of premature stop codons in the 
transcript of the mutated dystrophin gene [93].   There is also burgeoning interest in 
the potential use of RNA polymerase I inhibitors in cancer therapy (reviewed in [94]).   
A number of possible avenues for the development of more-refined therapeutic 
approaches that target the ribosome open up if ribosome heterogeneity proves a 
way that distinguishes cells within different tissues, cells in different states of 
development, activation or disease and/or that substantially alters the efficiency with 
which specific mRNAs are translated.  
 
6.1. The hypothetical immunoribosome and the immune response as a target 
for ribosome-based therapy 
 
The provocation that a highly specialised ribosome, termed the immunoribosome, 
exists is particularly intriguing [95].  The model proposed accounts for the rapidity of 
viral-antigen presentation from stable viral proteins.  The proposal is that this as yet 
hypothetical specialised ribosome is responsible for the production of peptides 
presented by MHC Class I molecules on activated T-cells that are, in the main, 
particularity transient components of proteins that, when produced in the accurate 
and functional form are, nonetheless, rapidly degraded (RPDs – rapidly degraded 
polypeptides).  The researchers propose that these peptides, named defective 
ribosomal products (DRiPs), are produced from tumour cells or intracellular 
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pathogens as polypeptides that fail to achieve native structure due to errors in their 
synthesis. The immunoribosomal population of the cell is a hypothetical subset of 
ribosomes dedicated to the production of DRiPs for antigen processing.   Advances 
in proteomic techniques for granular study of ribosome heterogeneity and 
preferential mRNA translation may provide an opportunity to identify 
immunoribosomes, if a real phenomenon, and in turn to ultimately harness the 
potential of these putative specialist ribosomes for therapeutic applications that could 
include cancer immunotherapy and T-cell-targeted immunosuppression. 
 
Agnostic to the existence of the immunoribosome, the immune response generally 
may be a process in which exploiting ribosome heterogeneity for therapeutic benefit 
offers particular opportunities.  It would seem likely, though still an idea to 
investigate, that the rapidly dividing cells of the activated immune system employ 
particular ribosome variants to achieve rapid translation transcripts pivotal in their 
expansion. 
 
6.2. Ribosome-associated cancers and the hypothetical cancer ribosome 
 
A number of cancers are associated with ribosomal gene abnormality.  Some 
features of these cancers, while not providing direct evidence for the involvement of 
ribosomes that are not all uniform and interchangeable in function, are nonetheless 
consistent with ribosomes being a heterogeneous population of organelles that differ 
between cells.  Incidences of gene copy-number changes in cancer are generally 
much lower than incidences of point mutations. However, this trend is reversed in the 
case of ribosomal protein gene mutations associated with cancer; abnormality in 
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ribosomal protein genes in cancer is more often through copy-number changes than 
point mutations [96]. This situation may reflect a requirement for tight control over the 
relative stoichiometry of production of specific ribosomal proteins, which would seem 
commensurate with normal cell function and controlled cell proliferation requiring a 
ribosome complement of very specific composition as would be likely in the case of 
functional ribosome heterogeneity.  Thus, although not direct evidence for the 
phenomenon, this observation made in cancer is arguablly supportive of the 
principle.  
 
Multiagent combination therapy cocktails are required to overcome the low efficacy 
of single-agent cancer therapies due to resistance development and to treat cancer 
with high efficacy and low toxicity.  The size and complexity of the ribosome makes it 
a good target for such approaches, some of which, such as use of RNA polymerase I 
inhibitors, are based on ‘starving’ cancer cells of ribosomes to prevent translation.  
However, ribosome heterogeneity created by the genetic abnormalities that underlie 
ribosome-related cancers is arguably the most promising new therapeutic target for 
ribosome-based cancer therapy. The hypothetical ‘onco-ribosome’ may be an 
attractive drug target.  This could be considered a form of abnormal ribosome 
heterogeneity or of ‘uncontrolled ribosome heterogeneity’.  High-resolution structures 
of human ribosomes bound to various antibiotics and, in future, of mutant ribosomes 
open the drug discovery field to finding new ribosomal inhibitors that interact 
specifically with defective ribosomes, which could be through the design of small 
molecules that bind specifically to ‘onco-ribosomes’.   Repurposed prokaryotic 
antibiotics that target the ribosome, identified by screening for interaction with 
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abnormal human cancer ribosomes, may also prove effective new therapeutic 
agents [96]. 
 
6.3. Other avenues for ribosome-targeted therapies 
 
In the same way that distinguishing features of the ribosomes of cancer cells or 
activated immune cells may provide therapeutic targets, so might we ultimately be 
able harness ribosome heterogeneity by co-administering a ribosome-targeted drug 
to manipulate the susceptibility of specific tissues to other drugs to improve 
specificity and reduce side effects.  An assault on cell-type-specific ribosomes 
through targeting their distinctive components to weaken the ability of cells to 
produce new proteins due to compromised mRNA translation may achieve this.  At 
the most-refined level of drug targeting, intracellular rRNA heterogeneity could 
potentially be exploited to target and prevent translation of specific transcripts, such 
as proteins responsible for disease symptoms, that are translated by ribosomes with 
druggable distinctive components.  The discovery that ribosomes containing 
RPS25/eS25 preferentially translate mRNAs encoding all stages of the vitamin B12 
pathway [40] tempts speculation that the paradigm may apply to other cellular 
pathways also.  This remains to be proven.  However, should this apply to pathways 
that are therapeutic targets for particular diseases then targeting drug treatment to 
heterogenous features of ribosomes may be particularly efficacious, akin to the 
strategy of Systems Pharmacology.  
 
A description of ribosome assembly and the state of current knowledge about the 
process is beyond the scope of this article, but is the subject of a comprehensive 
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recent review [52].  Differences in individual components of the assembly machinery 
responsible for the production of variant ribosomes offer another potential target to 
deliver therapy targeted to specific cells or intracellular ribosome subpopulations.   
 
The therapeutic potential of ribosome heterogeneity may extend, either through 
targeted manipulation of ribosome activity in the intracellular environment or in cell-
free protein synthesis systems, to synthesis of therapeutic peptides such as 
antibodies, insulin and tissue plasminogen activator.  Creation of bespoke ribosomes 
optimised for the translation of the corresponding mRNAs in engineered cells or cell-
free systems may add to the synthetic biology toolkit and improve the process of 
producing recombinant proteins therapeutics. 
 
Figure 2 presents the range possible approaches to exploiting intercellular and 
intracellular ribosome heterogeneity for therapeutic application discussed above. 
 
7. Conclusions and Future Directions 
 
A large body of data now demonstrates that cells in the same organism can differ in 
their complement of ribosomal components, including differences in ribosomal 
protein and/or RNA content and modification.  Thus, the principle that ribosome 
heterogeneity exits on an intercellular basis is probably unequivocal.  However, 
major questions remain concerning ribosome heterogeneity on an intracellular level 
and, more importantly, concerning if differences in ribosome composition either 
between or within cells have any functional consequences. 
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The advancement of proteomic techniques to a point where the ribosomal protein 
composition of individual ribosomes can be determined now poises the field at a 
nexus to determine how much of the capacity for individual ribosome heterogeneity 
is exploited.  However, determining directly that ribosomes of specific composition 
differ in their function, for example with respect to relative efficiency with which they 
translate specific mRNAs, will be an ongoing challenge.   One way forward may be 
to harness future improved understanding of how the process of ribosome assembly 
introduces such heterogenous features and recapitulate this ex-vivo to build 
synthetic ribosomes to test in cell-free systems.  We may also be able to exploit such 
approaches for therapeutic benefit in the future through customisation of synthetic 
ribosomes to optimise the synthesis of peptide-based therapeutics.  Detailed 
knowledge of how the process of ribosome assembly introduces heterogeneity may 
also reveal druggable targets to affect differentially affect the synthesis of specific 
ribosome variants for therapeutic benefit in vivo. 
 
As advances in structural biology reveal greater ribosome structural detail, rational 
design of drugs to target specific ribosome variants may become feasible. Putative 
variants that may be particularly high-priority drug targets include the proposed 
immunoribosomes of activated T-cells, for the purpose of cancer immunotherapy and 
T-cell-targeted immunosuppression, and the proposed oncoribosome, to target 
cancer cells. 
 
In summary, ribosome heterogeneity stands poised to potentially become a major 
new target for therapeutic intervention.  However, advances in understanding the 
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basic principles of ribosome heterogeneity and the assembly processes responsible 






Figure 1.  Potential variations in ribosome composition.  Ribosomal RNA (rRNA) 
is depicted in blue (large subunit) or green (small subunit).  Proteins (except where 
variant) are depicted in yellow. Alternative colouring (or, for rRNA shading pattern) 
indicates variation.  The tables show the composition of the bacterial and eukaryotic 
ribosome.  
 
Figure 2.  Potential approaches to exploiting features of ribosome 
heterogeneity for therapeutic benefit.  Coloured arrows point to potential drug 
target sites (shown in the same colour) on ribosomes that differ between cells or 
ribosomes with cells.  A flat arrowhead (and colour difference) indicates the drug 
does not interact with the site indicated. A round arrowhead indicates blocking a 
process.  An effective therapeutic strike is shown as disordered ribosome structure 
and fragmentation of the cell membrane. 
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Table 1.  Ribosomopathies: diseases caused by defects in ribosomal proteins 
or in components of the ribosome biogenesis pathway.  Adapted from [52]. 
 
Disease  OMIM Affected 
gene(s)* 
Clinical features 
Diamond-Blackfan anaemia [53, 
54] 












anaemia, cataracts, cleft palate, glaucoma, 
hypertelorism, malformed or absent 
thumbs, microcephaly, micrognathia, ptosis, 
short, webbed neck, strabismus 
5q-myelodysplastic 
Syndrome [55] 
153550 RPS14 anaemia,  dysmegakaryopoiesis, thrombocytosis 
 
isolated congenital asplenia 
[46] 
271400 RPSA absence of spleen, immunodeficiency 
RPS23-related 
Ribosomopathy [56] 
617412 RPS23 autism spectrum disorder, epicanthic folds in eyes, extra front teeth, 
facial asymmetry, foetal finger pads, hearing loss, high palate, 
intellectual disability, low back hairline, microcephaly, 
simian palmar creases, 








cleft palate, craniofacial defects, hearing loss, micrognathia,microtia, 
midface hypoplasia  
postaxial acrofacial 
dysostosis (POADS) [60] 
263750 DHODH craniofacial defects, postaxial limb deformities  
 
Roberts syndrome [61] 268300 ESCO2 craniofacial defects, limb malformations, prenatal growth 
retardation 
Scleroderma [62] 181750 UTP14A hardened/thickened skin, muscle weakness, ulcers/sores, swollen 
joints, fingers or toes,  
 






bone marrow failure, immunodeficiency, mucocutaneous 
abnormalities, pulmonary fibrosis  
 
Bowen-Conradi syndrome [67] 211180 EMG1 camptodactyly, growth retardation, microcephaly, facial deformities, 
joint 
abnormalities, micrognathia, psychomotor delay, rockerbottom feet 
cartilage-hair hypoplasia [68] 250250 RMRP Bone deformities, hair growth abnormalities, short stature 
North American Indian 
childhood cirrhosis [69, 70] 
604901 UTP4 
NOL11 







bone marrow dysfunction, exocrine pancreatic insufficiency, 
leukaemia, skeletal abnormalities 
alopecia, neurological and 
endocrinopathy 
syndrome (ANE) [75, 76] 
612079 RBM28 alopecia, endocrinopathy, neurological defects  
aplasia cutis congenital [77] 107600 BMS1 skin (especially scalp) defects  
 
leukoencephalopathy, 
intercranial calcifications and 
cysts [78] 
 
614561 SNORD118 leukoencephalopathy, intercranial calcifications and cysts 
 
cancer-prone bone marrow 
failure syndrome [79] 
617052 DNAJC21 Acute myeloid leukaemia, bone marrow failure, decreased bone 
density, microcephaly, short stature 
 
 
X-linked intellectual disability, 
cerebellar hypoplasia and 





*The prefix RP denotes ribosomal protein genes.  Other genes listed are involved in 
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